News Vir Biotechnology Announces New Clinical Data From its Broad Hepatitis B Program Continue Reading Previous Arbutus Presents New Data on AB-729, AB-836 and AB-101 at the EASL International Liver Congress™ 2022 and Provides AB-836 Clinical UpdateNext Madrigal Pharmaceuticals Presents Late-Breaking Phase 3 NASH Data and Multiple Oral Abstracts at EASL’s International Liver Congress™ Related Stories News Georgia Benefits from 20,000 New Kinetic Fiber Builds News Oklahoma Benefits from 7,900 new Kinetic Fiber Builds News Kentucky Benefits from 12,600 New Kinetic Fiber Builds News Florida Benefits from 5,900 New Kinetic Fiber Builds News Texas Benefits from 9,000 New Kinetic Fiber Builds News North Carolina Benefits from 7,800 New Kinetic Fiber Builds
